Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07104240 · ClinicalTrials.gov registry record · NA
A Vaccine Promotion Package (TweenVax) to Improve Adolescent HPV Vaccination, TweenVax Trial
A NA study of Human Papillomavirus-Related Carcinoma, sponsored by Emory University.
- Recruiting
- Registry status
- NA
- Development phase
- 1,836
- Enrollment target
- 1
- Study location
NCT07104240: Recruiting NA study of Human Papillomavirus-Related Carcinoma, sponsored by Emory University.
NCT07104240 is a NA study of Human Papillomavirus-Related Carcinoma that is actively recruiting participants, run by Emory University. The registered enrollment target is 1,836 participants, above the 145-participant average among 7 other Human Papillomavirus-Related Carcinoma trials with a reported enrollment target (1166% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07104240, a NA study of Human Papillomavirus-Related Carcinoma, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,836 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial compares the effect of a vaccine promotional intervention, TweenVax, to standard of care vaccination promotion practices on rates of human papillomavirus (HPV) vaccination in adolescents. HPV vaccination has been identified as a priority for cancer prevention and control by the Cancer Moonshot Blue Ribbon Panel, which estimated that increasing HPV vaccination rates can prevent 400,000 HPV-related cancers in the next 5-10 years. The goal is for HPV vaccinations to be completed by the age of 13. It has been estimated that only about 16% of adolescents were fully up to date with HPV vaccines by age 13. Strong and consistent provider recommendations have been shown to play an important role in the uptake of vaccines. In addition, education and information received by parents may improve the strength of recommendations by providers. The TweenVax intervention includes practice, provider, parent and patient level education to teach best practices, help with vaccine messaging, and give correct and easy to understand information to parents. Providing practice, provider and parent level access to TweenVax may be more effective than current vaccine promotion practices in improving HPV vaccination rates in adolescents.
Primary Outcome
Will do a direct comparison of rates in the intervention groups relative to the control group. However, if there is an imbalance in covariates between the arms, will then use multivariable regression, accounting for clinic-level clustering and key covariates. If needed, the initial regression model will be a log-binomial regression, to directly estimate relative risk; however, the final modeling choice will be dependent on the actual distribution of the data which may necessitate an alternative
Conditions Studied
Interventions
- OTHER Best Practice
- OTHER Educational Intervention
- OTHER Health Promotion and Education
- OTHER Internet-Based Intervention
Study Locations (1)
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,836 participants |
| Start Date | 2025-05-02 |
| Est. Completion | 2028-03-06 |
| Phase | NA |
What NCT07104240 shows while recruiting
NCT07104240 is an interventional study that assigns participants to a tested intervention. Its 1,836 participants enrollment target places it among the larger protocols in the corpus, above the 145-participant average among 7 other Human Papillomavirus-Related Carcinoma trials with a reported enrollment target (1166% higher).
The record links to 1 condition, with Human Papillomavirus-Related Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Best Practice is the first listed.
NCT07104240 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT07104240 about?
NCT07104240 is a clinical study titled "A Vaccine Promotion Package (TweenVax) to Improve Adolescent HPV Vaccination, TweenVax Trial". This clinical trial compares the effect of a vaccine promotional intervention, TweenVax, to standard of care vaccination promotion practices on rates of human papillomavirus (HPV) vaccination in adolescents. HPV vaccination has been identified as a priority for cancer prevention and control by the C...
What is the current status of trial NCT07104240?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,836 participants. The study started on 2025-05-02. Estimated completion is 2028-03-06.
What conditions does trial NCT07104240 study?
This clinical trial studies the following conditions: Human Papillomavirus-Related Carcinoma.
What interventions are being tested in trial NCT07104240?
The interventions under investigation include: Best Practice (OTHER), Educational Intervention (OTHER), Health Promotion and Education (OTHER), Internet-Based Intervention (OTHER).
Who is sponsoring clinical trial NCT07104240?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07104240 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papillomavirus-Related Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MeFirst: A Tailored Intervention to HPV Vaccine Decision Making
COMPLETED · NA
-
Testing RG1-VLP Vaccine to Prevent HPV-related Cancers
RECRUITING · Phase 1
-
MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer
ACTIVE NOT RECRUITING · Phase 1
-
HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA
ACTIVE NOT RECRUITING · Phase 1
-
Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants
ACTIVE NOT RECRUITING · Phase 2
-
Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06740630 · 1,840 participants · Phase 3
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
- NCT06465810 · 1,850 participants
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
- NCT06580080 · 1,850 participants · NA
Evaluation of Are You Ready?
- NCT05897788 · 1,808 participants · NA
Text-Messaging Telehealth and Contingency Management for Opioid Use Disorder Treatment Engagement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI